Albireo to Present at Upcoming Investor Conferences
Albireo Pharma, Inc. (Nasdaq: ALBO), focused on rare pediatric liver diseases, has announced presentations by CEO Ron Cooper and CFO Simon Harford at upcoming investor conferences. Key events include the 2021 Virtual Wells Fargo Healthcare Conference on September 9, H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and Baird 2021 Global Healthcare Conference on September 14. Webcasts will be accessible through Albireo’s website, with archived versions available for 30 days post-event.
Albireo is developing bile acid modulators and has FDA-approved Bylvay for PFIC treatment.
- None.
- None.
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Company’s management team will be presenting at the following investor conferences:
- 2021 Virtual Wells Fargo Healthcare Conference
Thursday, September 9 at 9:20 a.m. ET
- H.C. Wainwright 23rd Annual Global Investment Conference
Monday, September 13 at 7:00 a.m. ET
- Baird 2021 Global Healthcare Conference
Tuesday, September 14 at 9:40 a.m. ET
The webcasts of the presentations will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcasts, it is recommended that users register at least 15 minutes prior to the scheduled start times. An archived version of the webcasts will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 30 days following the event.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFIC and has been submitted for pricing and reimbursement approval. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.
Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lauren Sneider, 857-300-1737, lauren.sneider@albireopharma.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
FAQ
When is Albireo Pharma presenting at the 2021 Virtual Wells Fargo Healthcare Conference?
What are the dates for Albireo's presentations at the H.C. Wainwright Conference?
What time will Albireo present at the Baird Global Healthcare Conference?
How can I access Albireo's conference webcasts?
What recent achievements does Albireo highlight in its press release?
